NRIX insider trading
HealthcareNurix Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Company website: www.nurixtx.com
NRIX insider activity at a glance
FilingIQ has scored 472 insider transactions for NRIX since Jul 28, 2020. The most recent filing in our index is dated May 5, 2026.
Across the full history, 0 open-market purchases
and 175 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NRIX insider trades is 61.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NRIX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding NRIX
Frequently asked
- How many insider trades does FilingIQ track for NRIX?
- FilingIQ tracks 472 Form 4 insider transactions for NRIX (Nurix Therapeutics, Inc.), covering filings from Jul 28, 2020 onwards. 27 of those were filed in the last 90 days.
- Are NRIX insiders net buyers or net sellers?
- Across the full Form 4 history for NRIX, 0 transactions (0%) were open-market purchases and 175 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NRIX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is NRIX in?
- Nurix Therapeutics, Inc. (NRIX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.57B.
Methodology & sources
Every NRIX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.